

84/LG/SE/JULY/2020/GBSL

July 08, 2020

To
The Manager (CRD)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001

To
The Manager
National Stock Exchange Of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code : 509079

Symbol : GUFICBIO

Dear Sirs,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

This is in reference with the Scheme of Amalgamation of Gufic Biosciences Limited ('the Company') with Gufic Lifesciences Private Limited ("GLPL") and their respective shareholders and creditors, for which "No Observation Letters" have been received by BSE Limited and National Stock Exchange of India Limited vide their letters dated April 15, 2020.

We are pleased to inform you that GLPL have been approved by South African Health Products Regulatory Authority (SAHPRA) to manufacture Vancomycin Inj 500mg and Vancomycin Inj 1gm, after its manufacturing facility situated at Navsari, Gujarat been inspected by the Competent Authority of Hungary, National Institute of Pharmacy and Nutrition and with this approval, GLPL can now expand its business in the territory of South Africa. The registration details are as follows:

Registration Number: 44/20.1.1/1037; 44/20.1.1/1038

Application Number: SAHPRA-F770F3

Product Name: Rubyvan 0,5 g; Rubyvan 1 g

Active Ingredient: Vancomycin Hydrochloride

Further, the Company has approached Hon'ble National Company Law Tribunal for further process of amalgamation. Post amalgamation, the Company will enjoy the benefits as stated hereinabove.

Kindly take the same on record.

Thanking You,

Yours faithfully,

For Gufic Biosciences Limited



Ami Shah

Company Secretary

Membership No. A39579